← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT06938880

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

Trial Parameters

Condition Advanced Solid Tumor
Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2025-05-20
Completion 2027-05
Interventions
ZGGS18 for InjectionZG005 for Injection

Brief Summary

This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.

Eligibility Criteria

Inclusion Criteria: * Fully understand this study and voluntarily sign the ICF. * Age 18-75 years, no gender restriction. * Patients with advanced solid tumors who have failed standard treatment or are intolerant to standard treatment, as confirmed by histopathology or cytology. Exclusion Criteria: * Medical history, CT scan, or MRI indicates the presence of CNS metastases. * Other malignancies within 5 years. * Any other reason deeming the participant unsuitable for the study, as judged by the investigator.

Related Trials